Literature DB >> 3006831

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease.

W Miller, P Flynn, J McCullough, H H Balfour, A Goldman, R Haake, P McGlave, N Ramsay, J Kersey.   

Abstract

Among 181 patients undergoing allogeneic bone marrow transplantation over a five-year period (1978 through 1982), cytomegalovirus (CMV) infection was a frequent and often lethal complication. Recipient pretransplant serology was the most important predictor of posttransplant CMV infection. CMV infection occurred in 26/137 seronegative recipients and in 28/44 seropositive recipients (P less than .001). Among patients who developed CMV infection, the time to infection was identical in seronegative and seropositive patients (median, 71 days post transplant). Bone marrow donor CMV serology did not significantly influence CMV infection rate. CMV infection was strongly associated with acute graft-v-host disease (AGVHD), occurring in 34/81 patients with AGVHD and 20/100 without GVHD (P less than .001). AGVHD preceded CMV infection by 33.7 days (mean) in patients developing both complications. Patients who developed CMV infections had also received more cellular blood products post transplant. These data suggest that CMV infection may occur through reactivation of latent virus (in seropositive recipients) or through exogenous exposure, possibly through transfused blood products, but that duration of immunoincompetence may be more critical than route of exposure in timing of clinically evident CMV infection. Prophylaxis tailored to the likely infectious source and more effective GVHD prevention both may be critical in preventing CMV infection after bone marrow transplantation.

Entities:  

Mesh:

Year:  1986        PMID: 3006831

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

Review 1.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  Risk factors for viral reactivation following bone marrow transplantation.

Authors:  D Pillay; A Webster; H G Prentice; P D Griffiths
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

3.  Increase in severity of graft versus host disease by cytomegalovirus.

Authors:  A L McCarthy; J S Malik Peiris; C E Taylor; M A Green; L Sviland; A D Pearson; A J Malcolm
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

4.  Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.

Authors:  Eun Sang Yi; Yae-Jean Kim
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

Review 5.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

6.  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Authors:  Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Yoo-Jin Kim; Sun Hee Park; Sun-Nam Park; Chang-Ki Min; Seok Lee; Hee-Je Kim; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Wan-Shik Shin; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

7.  Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: functional analyses of lymphocytes and correlation with immunophenotypic recovery following transplantation.

Authors:  H Kook; F Goldman; R Giller; N Goeken; C Peters; M Comito; S Rumelhart; M Holida; N Lee; M Trigg
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

Review 8.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Tetsuya Eto; Koji Nagafuji; Kenjiro Kamezaki; Yayoi Matsuo; Goichi Yoshimoto; Naoki Harada; Maki Yoshida; Hideho Henzan; Ken Takase; Toshihiro Miyamoto; Koichi Akashi; Mine Harada; Takanori Teshima
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

10.  Pulmonary disease following allogeneic bone marrow transplantation.

Authors:  M Murray; D S O'Briain; J Prichard; S R McCann
Journal:  Ir J Med Sci       Date:  1989-02       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.